Quarterly report pursuant to Section 13 or 15(d)

LICENSE AGREEMENTS - Additional Information - (Detail)

v3.20.2
LICENSE AGREEMENTS - Additional Information - (Detail) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Oct. 23, 2020
Oct. 09, 2020
Oct. 31, 2020
Mar. 31, 2020
Sep. 30, 2020
License agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Stock Issued During Period, Value, Issued for Services       $ 2.6  
Activesite Pharmaceuticals Inc          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Maximum Amount of Milestone Events         $ 46.5
First milestone payment due after completion of the preclinical work         $ 1.0
Royalties percentage         2.00%
Subsequent events          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Proceeds from private placement of equity shares   $ 41.0      
Xoma | License agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Stock Issued During Period, Shares, Other         162,000
Xoma | Subsequent events          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Proceeds from private placement of equity shares   $ 20.0 $ 41.0    
Payments of outstanding balance of license $ 1.4        
Put Option [Member] | Xoma | License agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Description Of Option Indexed To Issuers Equity Shares         Xoma was permitted to exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter.